VIENNA, Austria, September 25 /PRNewswire/ -- The successful progress of several vaccine programmes run by AFFiRiS GmbH has prompted investor MIG AG to increase its investment in the company. It has set up two new funds - MIG 5 and MIG 7 - to give private investors in Germany and Austria the opportunity to invest in this promising biotech company. The company decided to take this step for two reasons. First, to ensure the early coverage of future capital demand for the continued successful development of vaccines against Alzheimer's disease and atherosclerosis and, second, the tremendous potential that the proprietary AFFITOME platform technology offers the global pharmaceutical market.
The investment group MIG-Fonds announced today that it has increased its investment in AFFiRiS by a further Euro 3 million. As a result, private investors now have another chance to share in the economic success of the biotech company via the MIG Fonds 5 and 7. This news is particularly relevant for private investors in Germany, who have immediate access to MIG 7. This provides investors with the opportunity to make a highly promising investment before the modified capital gains tax comes into force in Germany. Therefore, after a year's holding period, any later profits made from this investment will be tax free.
AFFiRiS will contribute to the success of these funds through its
proprietary AFFITOME technology, which is based on the process of molecular
mimicry. This technology enables the development of customized vaccines
known as AFFITOPE. Dr. Walter Schmidt, co-founder and company CEO, explains
the key to the company's AFFiRiS vaccine strategy: "Our patented AFFITOME
technology enables scientists to create both molecules with very specific
binding characteristics and molecules that differ in structure but exhibit
identical binding characteristics. We are currently using these strengths
in the development of vaccines against Alzheimer's disease. In the future,
|SOURCE AFFiRiS GmbH|
Copyright©2008 PR Newswire.
All rights reserved